«Although TKIs such as the first - generation TKI imatinib mesylate (IM) and the second - generation TKIs dasatinib and nilotinib have markedly improved the prognosis of patients with chronic phase CML, a cure remains elusive. (sciencedaily.com)
The drug imatinib mesylate (Gleevec) is shown to be effective against chronic myelogenous leukemia (CML). (cancerresearch.org)
[12] It was marketed in 2001 by Novartis as imatinib mesylate (Gleevec in the US, Glivec in Europe). (en.wikipedia.org)